First, because of the restriction on the use of aliskiren in clinical trials in China, our study did not test the effect of the oral administration of aliskiren on the Tie2/PI3K/Akt/eNOS pathway in circulating EPCs in patients with hypertension. Here, AKT1 is linked to hypertensive disorder.